Adult, adolescent & childn ≥4 yr, ≥30 kg Initially 400 mg daily, may be increased by 400 mg/day increments every 2 days. Max: ≥70.1 kg 3,200 mg/day, 50.1-70 kg 2,400 mg/day, 30-50 kg 1,800 mg/day. Patient >30 kg receiving valproate Initially 400 mg daily, may be increased by 400 mg/day increments every other day. Max: ≥70.1 kg 2,200 mg/day, 50.1-70 kg 1,600 mg/day, 30-50 kg 1,200 mg/day. Childn ≥4 yr & <30 kg not receiving valproate Initially 200 mg daily, may be increased by 200 mg/day increments every 2 days up to max of 1,000 mg/day. <30 kg receiving valproate Initially 200 mg daily, may be increased by 200 mg/day after 2 days to max of 600 mg/day.
Status epilepticus. W/draw gradually to reduce the possibility of seizures on w/drawal. Associated w/ dizziness, somnolence, ataxia & gait disturbances. Serious antiepileptic drug hypersensitivity syndrome including drug reaction w/ eosinophilia & systemic symptoms (DRESS) & Stevens-Johnson syndrome. Lymphadenopathy, liver function test abnormalities & hematuria. Discontinue use & start alternative treatment if antiepileptic drug hypersensitivity syndrome is suspected. Decreased in QTc interval proportional to conc. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Monitor for signs of suicidal ideation & behaviour. May cause minor to major influence on the ability to drive & use machinery. Patients w/ mild to moderate hepatic impairment. Not recommended in patients w/ severe hepatic impairment. Women of childbearing potential must use effective contraception during treatment. Should not be used during pregnancy. Avoid breast-feeding during treatment.
Manage Account
Change Password
Sign Out
